Ascletis Pharma Inc. (ASCLF)

Overview

Ascletis Pharma Inc., established in 2013 and headquartered in Hangzhou, the People's Republic of China, stands as a pioneering figure within the biotechnology sector. The company's operations span across the globe, with a significant presence in Mainland China and other international markets. Ascletis Pharma Inc. dedicates itself to the discovery, development, and commercialization of innovative pharmaceutical solutions. With a robust focus on addressing various viral diseases, liver diseases, and oncology, the company has deployed an impressive array of pharmaceutical products and is actively involved in groundbreaking research to tackle some of the most challenging medical conditions faced globally.

Products and Services

• Ritonavir Oral Tablet - Functions as a pharmacokinetic booster for several oral antiviral drugs targeting viral proteases. Notably, it plays a critical role as a component of Paxlovid, an approved oral antiviral medication.
• ASCLEVIR & GANOVO - These are designated treatments for the Hepatitis C virus, offering effective antiviral therapies to combat this pervasive liver disease.
• ASC22 - Currently under development, ASC22 shows promise in treating chronic hepatitis B (CHB), aiming to improve outcomes for patients battling this long-term infection.
• ASC42 - Targeting a functional cure for chronic hepatitis B, this experimental therapy explores new frontiers in the pursuit of eradicating HBV infections.
• ASC10 & ASC11 - These candidates are in the development stages for addressing COVID-19, reflecting Ascletis Pharma Inc.'s commitment to combating the global pandemic.
• ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC - Focus on treating non-alcoholic steatohepatitis (NASH), a liver disease with significant unmet medical need.
• ASC42 for Primary Biliary Cholangitis - Another facet of the company's liver disease portfolio, ASC42 is being developed to treat primary biliary cholangitis, a rare liver condition.
• ASC40 for Oncological Conditions - Reflecting its versatile application in therapy, ASC40 is under development for recurrent glioblastoma, drug-resistant breast cancer, and KRAS mutant non-small cell lung cancer.
• ASC61 & ASC63 - These experimental therapies are designed for advanced solid tumors, indicative of Ascletis Pharma Inc.'s foray into comprehensive cancer care.
• ASC60 - Targeting solid tumors, this treatment option showcases the company's efforts in expanding its oncology pipeline.
• ASC40 for Acne - In addition to its oncological applications, ASC40 is also being explored as a potential treatment for acne, signifying the company's diverse approach to therapeutic development.